NOD2 genetic variants predispose one of two familial adenomatous polyposis siblings to pouchitis through microbiome dysbiosis.

Related Articles NOD2 genetic variants predispose one of two familial adenomatous polyposis siblings to pouchitis through microbiome dysbiosis. J Crohns Colitis. 2017 Jun 19;: Authors: Schieffer KM, Wright JR, Harris LR, Deiling S, Yang Z, Lamendella R, Yochum GS, Koltun WA Abstract Background and Aims: Individuals with familial adenomatous polyposis (FAP) may undergo a total proctocolectomy with ileal pouch-anal anastomosis (IPAA) to surgically treat their disease. Inflammation of the ileal pouch, termed pouchitis, is uncommon in FAP patients but prevalent in patients who received IPAA for ulcerative colitis, a type…

Read More

Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN.

Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN. J Crohns Colitis. 2017 Jun 09;: Authors: Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A, Uhlig HH, Posovsky C, Kolho KL, Jakobsen C, Cohen S, Shouval DS, de Meij T, Martin-de-Carpi J, Richmond L, Bronsky J, Friedman M, Turner D Abstract Background: Vedolizumab, an anti-integrin antibody, has proven to be effective in adults with Inflammatory Bowel Disease (IBD), but…

Read More

Serial Tuberculosis screening in inflammatory bowel disease patients under anti-TNF╬▒ therapy.

Serial Tuberculosis screening in inflammatory bowel disease patients under anti-TNFα therapy. J Crohns Colitis. 2017 Jun 09;: Authors: Abreu C, Afonso J, Dias CC, Ruas R, Sarmento A, Magro F Abstract Background and aims: One of the adverse effects of the tumour necrosis factor-α monoclonal antibodies for the treatment of immune-mediated inflammatory diseases is a higher propensity for tuberculosis development. The aim of this study was to explore the utility and sensitivity of serial tuberculosis screening during anti-TNFα treatment. Methods: A cohort of 46 inflammatory bowel disease patients on infliximab…

Read More

Genetic mouse models with intestinal-specific tight junction deletion resemble an ulcerative colitis phenotype.

Genetic mouse models with intestinal-specific tight junction deletion resemble an ulcerative colitis phenotype. J Crohns Colitis. 2017 May 27;: Authors: Stremmel W, Staffer S, Schneider MJ, Gan-Schreier H, Wannhoff A, Stuhrmann N, Gauss A, Wolburg H, Mahringer A, Swidsinski A, Efferth T Abstract Background and Aims: A key pathogenetic feature of ulcerative colitis(UC) is an intrinsic low mucus phosphatidylcholine(PC) content. Recently, a paracellular transport for PC across tight junctions(TJ) was described, suggesting TJ disturbance as cause of diminished luminal PC transport. Therefore we aimed to generate mutant mice with TJ…

Read More

Exclusive enteral nutrition therapy in pediatric Crohn’s disease results in long-term avoidance of corticosteroids: results of a propensity-score matched cohort analysis.

Exclusive enteral nutrition therapy in pediatric Crohn’s disease results in long-term avoidance of corticosteroids: results of a propensity-score matched cohort analysis. J Crohns Colitis. 2017 May 27;: Authors: Connors J, Basseri S, Grant A, Giffin N, Mahdi G, Noble A, Rashid M, Otley A, Van Limbergen J Abstract Background & Aims: Exclusive enteral nutrition (EEN) is recommended as first-line induction therapy for pediatric Crohn’s disease (CD) although corticosteroids (CS) are still used commonly. Our aim was to compare short- and long-term disease outcomes of pediatric CD patients initially managed with…

Read More

Positioning ustekinumab in Crohn’s disease: from clinical evidence to clinical practice.

Positioning ustekinumab in Crohn’s disease: from clinical evidence to clinical practice. J Crohns Colitis. 2017 Jun 02;: Authors: Danese S, Bonovas S, Peyrin-Biroulet L Abstract Biological medicines have revolutionized the treatment of Crohn’s disease (CD). Yet, the management of patients not responding to tumor necrosis factor (TNF) antagonists remains a clinical challenge. Ustekinumab is a human monoclonal antibody blocking the biological activity of interleukins 12 and 23, which regulate the immune system and immune-mediated inflammatory disorders. It has recently been approved for the treatment of adult patients with moderately to…

Read More

Occurrence of anaemia in the first year of inflammatory bowel disease in a European population-based inception cohort – An ECCO-EpiCom study.

Occurrence of anaemia in the first year of inflammatory bowel disease in a European population-based inception cohort – An ECCO-EpiCom study. J Crohns Colitis. 2017 May 31;: Authors: Burisch J, Vegh Z, Katsanos KH, Christodoulou DK, Lazar D, Goldis A, O’Morain C, Fernandez A, Pereira S, Myers S, Sebastian S, Pedersen N, Olsen J, Nielsen KR, Schwartz D, Odes S, Almer S, Halfvarson J, Turk N, Cukovic-Cavka S, Nikulina I, Belousova E, Duricova D, Bortlik M, Shonová O, Salupere R, Barros L, Magro F, Jonaitis L, Kupcinskas L, Turcan S,…

Read More

Dietary Therapy with the Crohn’s Disease Exclusion Diet is a Successful Strategy for Induction of Remission in Children and Adults Failing Biological Therapy.

Dietary Therapy with the Crohn’s Disease Exclusion Diet is a Successful Strategy for Induction of Remission in Children and Adults Failing Biological Therapy. J Crohns Colitis. 2017 May 19;: Authors: Sigall Boneh R, Sarbagili-Shabat C, Yanai H, Chermesh I, Ben Avraham S, Boaz M, Levine A Abstract Background: Loss of response (LoR) to biologics in Crohn’s disease (CD) is a significant clinical problem. Dietary therapy as a treatment strategy in this setting has not been previously reported. We report the use of dietary strategies using enteral nutrition coupled with the…

Read More
<< Go Back